DXI Capital Corp.

DXI Capital Corp. is pleased to provide an update on its proposed acquisition of V.V.T. Med Ltd. and Exiteam Acquisition Corp. , as outlined in its press releases dated May 21, 2025, March 25, 2025, November 28, 2024 and September 30, 2024 . The resulting company following the completion of the Proposed Transaction is referred to as the "Resulting [...]

DXI Capital Corp. , V.V.T. Med Ltd. and Exiteam Acquisition Corp. are pleased to announce that, further to DXI's press release dated March 25, 2025, DXI has filed a filing statement, dated effective May 15, 2025, with the TSX Venture Exchange in connection with its previously announced reverse take-over transaction of DXI by VVT and EAC . The [...]

DXI Capital Corp. , V.V.T. Med Ltd. and Exiteam Acquisition Corp. are pleased to announce that the TSX Venture Exchange has conditionally approved the previously announced reverse take-over transaction of DXI by VVT and EAC, as outlined in its press releases dated November 28, 2024, October 1, 2024 and November 24, 2023 . The resulting company [...]

DXI Capital is pleased to provide an update on its proposed acquisition of V.V.T. Med Ltd. and Exiteam Acquisition, as outlined in its press release dated Sept 30, 2024. The Company announces that its fulsome initial submission regarding this Proposed Transaction has now been submitted to the TSX-V for review and comment. Subject to the [...]

DXI Capital is pleased to announce that it has entered into a non-binding letter of intent dated Nov 22, 2023 with V.V.T. Med Ltd., an Israeli corporation, and Exiteam Acquisition Corp., pursuant to which DXI has agreed to acquire all of the issued and outstanding shares in the capital of VVT and EAC, as well as all other issued securities of VVT [...]

DXI Capital is pleased to announce the results of its annual general meeting of shareholders held on Thursday May 19, 2022, in Vancouver. AGM Results: The nominees listed in the management information circular, which was mailed to DXI Capital shareholders of record as of March 30, 2022, were elected to the board of directors of the Company to hold [...]

DXI Capital files on Sedar its YE 2020 annual audited financial statements. The Company is now well positioned to source and support a qualifying transaction to leverage DXI Capital's network and lineague in the North American public markets. The Company is actively seeking an impactful tailwind business with a strong, well capitalized management [...]

DXI Capital is pleased to announce that Mr. Sean Hodgins, CPA-CA, CPA has joined DXI as Chief Financial Officer and Chief Operating Officer, and engaged the services of Tandem Innovation Group Inc. to assist in the search for a suitable business transaction. Mr. Hodgins is a veteran of the high tech and life sciences industries with over 20 years [...]

DXI Capital Corp. , further to the Company's news release dated October 23, 2020, the Company announces that it has issued 100,153 shares at a deemed price of $0.475 per share to settle a total of $47,572.68 in debt owed to various creditors. The shares are subject to a statutory hold period expiring on March 20, 2021. The remaining balance of [...]

DXI Capital Corp. , further to the Company's news release dated September 29, 2020, the Company announces that it has issued 8,980,638 shares at a deemed price of $0.475 per share to settle a total of $4,265,803.05 in debt owed to various creditors. The shares are subject to a statutory hold period expiring on February 23, 2021. A remaining amount [...]